Diffusion of Innovation ; Humans ; Medical Oncology ; Neurology ; methods

Value-based care model has been evolving to organize medical services around the patient and provide the full cycle of care for a medical condition. The full cycle of care model encompasses inpatient, outpatient, rehabilitation as well as supportive care such as palliative care and nutrition support. Cancer rehabilitation and palliative care have emerged as two important parts of value-based practice for oncology patients. More clinical evidence suggests that early intervention of oncology rehabilitation program and palliative care are likely to improve the patient outcome and reduce the overall medical cost for the patient and his or her family as well as for medical service providers. Although interest has been raised in Chinese oncologists, but effectiveness of incorporating these two services in clinical practices has not been adequately demonstrated. An understanding of scope of cancer rehabilitation and palliative care may help facilitate the integration of both into the oncology care continuum in efforts to improve patients' physical, psychological, cognitive, functional health and quality of life.
Humans ; Medical Oncology ; methods ; Neoplasms ; Palliative Care ; methods ; Quality of Life

Humans ; Medical Oncology ; Neoplasms ; drug therapy ; genetics ; Pharmacogenetics ; methods

Global Health ; Humans ; Medical Oncology ; methods ; organization & administration ; trends ; Neoplasms ; therapy ; Philosophy, Medical

Genome-guided oncology refers to a new treatment concept that transcends histological classification and pathological ty-ping and uses drugs according to the genetic characteristics of tumors. New drug development technology and clinical trial design based on this concept provide new ideas for the clinical application of precision oncology. The multi-component and multi-target characteristics of Chinese medicine provide rich resources for the development of tumor-targeting drugs from natural products, and the design of the master protocol trial aiming at the characteristics of precision oncology supports the rapid clinical screening of effective tumor-targeting drugs. The emergence of the synthetic lethality strategy breaks through the bottleneck that the drug can only target the oncogene but cannot do anything to the tumor suppressor gene with the loss-of-function mutation in the past. With the rapid development of high-throughput sequencing technology, the cost of sequencing is also decreasing. For the development of tumor-targeting drugs, how to keep up with the update speed of target information is a difficult problem of concern. Based on the integration of innovative ideas and me-thods of precision oncology, network pharmacology, and synthetic lethality strategy on synthetic lethal interaction network of antitumor Chinese medicine compatibility formula design, and the combination of improvement of innovative clinical trial methods, such as master protocol trial, basket trial, and umbrella trial, unique advantages of Chinese medicine are expected to be exerted beyond the antibody-based drugs and small molecule-based drugs and corresponding targeted drugs are potentially developed for clinical application.
Humans ; Neoplasms/genetics* ; Medicine, Chinese Traditional ; Precision Medicine/methods* ; Medical Oncology ; Antineoplastic Agents/therapeutic use*

Tumor is one of the fateful diseases that human must confront. Currently, quantitative research is still the principal body of the research on cancer. Qualitative research can compensate the limitations of quantitative research in evaluating therapeutic effects on cancer, it can profoundly understand the attitude, experience, confidence, presumable problems and obstacles of doctors and patients to the therapy. This article introduces the necessity and general situation of development in applying qualitative research methods in the researches on tumor, and the main problems and developing tendency for extending in China.
Humans ; Medical Oncology ; methods ; Medicine, Chinese Traditional ; methods ; Neoplasms ; therapy ; Physician-Patient Relations ; Qualitative Research ; Research Design

Diagnostic Imaging ; trends ; Humans ; Medical Oncology ; methods ; trends ; Neoplasms ; diagnosis ; genetics ; therapy ; Patient Care Management ; methods ; trends

To improve cancer pain management, the Medical Oncology Department of Sun Yat-sen University Cancer Center (SYSUCC) launched the Good Pain Management (GPM) Ward Program, which has been recognized by the Chinese Ministry of Health and promoted throughout the nation. This retrospective case-control study was designed to evaluate the effectiveness of the program. Patients diagnosed with malignant solid tumors with bone metastasis were eligible. Patients who were admitted 6 months before the initiation of the GPM program were used as the control group, and patients admitted 6 months after the initiation of the program were used as the GPM group. The pain-reporting rate and pain management index (PMI) were calculated. The pain levels before and after pain management were compared. A total of 475 patients (244 in the control group and 231 in the GPM group) were analyzed. The pain-reporting rate of the GPM group was significantly higher than that of the control group (62.8% vs. 37.7%, P < 0.001). The PMI of the GPM group was significantly higher than that of the control group (0.083 vs. -0.261, P < 0.001). Therefore, the GPM Ward Program improved the pain management of cancer patients and provided experience for improving cancer pain management in the future.
Aged ; Bone Neoplasms ; Case-Control Studies ; China ; Humans ; Medical Oncology ; Neoplasms ; Pain ; Pain Management ; methods ; Pain Measurement ; Retrospective Studies

Female ; History, 20th Century ; Humans ; Mass Screening ; methods ; Medical Oncology ; history ; Singapore ; Uterine Cervical Neoplasms ; diagnosis ; Women's Health ; history

OBJECTIVE: According to recent European Society of Medical Oncology, European Society of Gynaecological Oncology and European Society of Radiotherapy and Oncology guidelines, adjuvant vaginal brachytherapy (VB) is optional in patients with intermediate risk (IR) and high-intermediate risk (HIR) endometrial cancer (EC). The aim of this French retrospective, multicenter study was to assess the impact of VB in these groups on local recurrence rate, local recurrence-free survival (RFS) and overall survival (OS). METHODS: Data of 191 patients with IR and HIR EC who underwent primary surgery with or without VB and no other adjuvant treatment between 2000 and 2016 were extracted from the FRANCOGYN database. Rate of local recurrence, OS and local RFS in these two groups were compared using the Kaplan-Meier method. RESULTS: The number of patients with IR and HIR EC were 118 and 73 respectively. VB was used in 92 patients in IR group and 43 in HIR group. Median follow-up was 22 months. In the HIR group, the local recurrence rate was significantly higher in the no adjuvant therapy group in comparison with the VB group (16.7% and 0% respectively, p=0.02). There was also a significant improvement in local RFS (p=0.01) in VB group. In IR EC, there is no significant difference on local recurrence rate (4.2% and 3.2%, respectively, p=1.00) or local RFS (p=0.54) between the two groups. CONCLUSIONS: VB is an efficient adjuvant treatment for patients with HIR EC. VB is not associated with an improvement of RFS or OS in IR EC patient.
Brachytherapy ; Endometrial Neoplasms ; Female ; Follow-Up Studies ; Humans ; Medical Oncology ; Methods ; Neoplasm Recurrence, Local ; Radiotherapy ; Recurrence ; Retrospective Studies